These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 38016379)

  • 1. Postbiotics: An alternative and innovative intervention for the therapy of inflammatory bowel disease.
    Kavita ; Om H; Chand U; Kushawaha PK
    Microbiol Res; 2024 Feb; 279():127550. PubMed ID: 38016379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.
    Eom T; Kim YS; Choi CH; Sadowsky MJ; Unno T
    J Microbiol; 2018 Mar; 56(3):189-198. PubMed ID: 29492876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Roles of Inflammation, Nutrient Availability and the Commensal Microbiota in Enteric Pathogen Infection.
    Stecher B
    Microbiol Spectr; 2015 Jun; 3(3):. PubMed ID: 26185088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Microbial Metabolites on Microbiota-Gut-Brain Axis in Inflammatory Bowel Disease.
    Banfi D; Moro E; Bosi A; Bistoletti M; Cerantola S; Crema F; Maggi F; Giron MC; Giaroni C; Baj A
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33562721
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Probiotics: Shaping the gut immunological responses.
    Filidou E; Kandilogiannakis L; Shrewsbury A; Kolios G; Kotzampassi K
    World J Gastroenterol; 2024 Apr; 30(15):2096-2108. PubMed ID: 38681982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of gut microbiota-bile acids axis by probiotics in inflammatory bowel disease.
    Li L; Liu T; Gu Y; Wang X; Xie R; Sun Y; Wang B; Cao H
    Front Immunol; 2022; 13():974305. PubMed ID: 36211363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Postbiotics-A Step Beyond Pre- and Probiotics.
    Żółkiewicz J; Marzec A; Ruszczyński M; Feleszko W
    Nutrients; 2020 Jul; 12(8):. PubMed ID: 32717965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prebiotics, Probiotics, Synbiotics, Paraprobiotics and Postbiotic Compounds in IBD.
    Martyniak A; Medyńska-Przęczek A; Wędrychowicz A; Skoczeń S; Tomasik PJ
    Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological and therapeutic interactions between bacteriophages, microbes and the host in inflammatory bowel disease.
    Babickova J; Gardlik R
    World J Gastroenterol; 2015 Oct; 21(40):11321-30. PubMed ID: 26525290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the gut microbiota in the treatment of inflammatory bowel diseases.
    Aggeletopoulou I; Konstantakis C; Assimakopoulos SF; Triantos C
    Microb Pathog; 2019 Dec; 137():103774. PubMed ID: 31586663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postbiotics and Their Potential Applications in Early Life Nutrition and Beyond.
    Wegh CAM; Geerlings SY; Knol J; Roeselers G; Belzer C
    Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Links Between Inflammatory Bowel Disease and Chronic Obstructive Pulmonary Disease.
    Raftery AL; Tsantikos E; Harris NL; Hibbs ML
    Front Immunol; 2020; 11():2144. PubMed ID: 33042125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent advances in gut Microbiota mediated therapeutic targets in inflammatory bowel diseases: Emerging modalities for future pharmacological implications.
    Shamoon M; Martin NM; O'Brien CL
    Pharmacol Res; 2019 Oct; 148():104344. PubMed ID: 31400403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Cross-Talk Between Microbiota-Derived Short-Chain Fatty Acids and the Host Mucosal Immune System Regulates Intestinal Homeostasis and Inflammatory Bowel Disease.
    Gonçalves P; Araújo JR; Di Santo JP
    Inflamm Bowel Dis; 2018 Feb; 24(3):558-572. PubMed ID: 29462379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intestinal microbiota in inflammatory bowel disease: friend of foe?
    Fava F; Danese S
    World J Gastroenterol; 2011 Feb; 17(5):557-66. PubMed ID: 21350704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-chain fatty acids affect the development of inflammatory bowel disease through intestinal barrier, immunology, and microbiota: A promising therapy?
    Peng K; Xia S; Xiao S; Yu Q
    J Gastroenterol Hepatol; 2022 Sep; 37(9):1710-1718. PubMed ID: 35906780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gut microbiota-derived metabolites as key actors in inflammatory bowel disease.
    Lavelle A; Sokol H
    Nat Rev Gastroenterol Hepatol; 2020 Apr; 17(4):223-237. PubMed ID: 32076145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postbiotics as Adjuvant Therapy in Cancer Care.
    Balendra V; Rosenfeld R; Amoroso C; Castagnone C; Rossino MG; Garrone O; Ghidini M
    Nutrients; 2024 Jul; 16(15):. PubMed ID: 39125280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current insights on the roles of gut microbiota in inflammatory bowel disease-associated extra-intestinal manifestations: pathophysiology and therapeutic targets.
    Tie Y; Huang Y; Chen R; Li L; Chen M; Zhang S
    Gut Microbes; 2023 Dec; 15(2):2265028. PubMed ID: 37822139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postbiotics in colorectal cancer: intervention mechanisms and perspectives.
    Xie W; Zhong YS; Li XJ; Kang YK; Peng QY; Ying HZ
    Front Microbiol; 2024; 15():1360225. PubMed ID: 38450163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.